Accuray Enters $8 Million Deal with RaySearch for Adaptive Radiation Therapy Integration
Accuray Inc. (NASDAQ:ARAY) has entered into an extended collaboration agreement with RaySearch Laboratories, a move aimed at advancing online adaptive radiation therapy solutions. The partnership integrates Accuray's imaging and photon-based treatment platforms with RaySearch’s planning software to streamline personalized cancer treatments. As part of the deal, Accuray will purchase $8 million in RayStation licenses, supporting commercialization efforts for these new therapies. The collaboration is a key component of Accuray's broader transformation strategy that has already exceeded its fiscal 2026 cost-cutting targets by over $20 million. However, the success of this initiative depends on factors such as clinic adoption rates and RaySearch’s ability to execute software integration smoothly without delays. Institutional interest in Accuray appears stable with an increase in hedge fund holdings during Q2 2026. TCW Group remains the largest institutional investor, holding a significant stake of over 15%.
Tickers: $ARAY
Topics: Corporate Partnership Healthcare Technology Radiation Therapy